依达赛珠单抗作为唯一逆转剂用于未知抗凝药导致的失代偿性出血性休克患者伴PT/INR升高
本文报告一例85岁女性,用药史不明,因上消化道出血导致呼吸困难及严重贫血,实验室检查示INR 6.43、血清肌酐2.21 mg/dL。在急诊科病情恶化,需气管插管、积极晶体液复苏、血制品及启动血管升压药。因无法区分华法林或达比加群所致凝血病且缺乏医疗信息,为预防血栓前状态,未使用凝血酶原复合物(PCC),仅用依达赛珠单抗逆转。给药30分钟后复查PT/INR分别为16.1 s和1.55,后证实患者仅服用达比加群。本病例提示达比加群在急性肾衰竭患者中可导致PT/INR极度升高,模拟华法林性凝血病,且依达赛珠单抗可快速显著纠正异常凝血指标。
要点
- 对于用药史不明、INR极度升高(6.43)的出血患者,达比加群所致凝血病可模拟华法林性凝血病,尤其在急性肾衰竭(肌酐2.21 mg/dL)时。
- 在无法区分华法林与达比加群所致凝血病时,为避免血栓前状态,可考虑不用PCC,仅用依达赛珠单抗逆转(本病例做法)。
- 依达赛珠单抗给药30分钟后PT/INR从6.43降至1.55,PT从无法测及降至16.1 s,显示快速纠正。
- 本病例患者为85岁女性,因上消化道出血出现失代偿性休克,需插管、晶体液复苏、血制品及血管升压药。
- 后证实患者仅服用达比加群,提示达比加群在急性肾衰竭时可导致PT/INR极度升高。
适用人群与场景
- 本病例为85岁女性,用药史不明,因上消化道出血导致呼吸困难、严重贫血及失代偿性休克,需气管插管、晶体液复苏、血制品及血管升压药。
- 原文未提及明确的纳入/排除人群标准,仅为单例病例报告。
诊断标准与关键阈值
- 原文未提及特定的诊断标准或评分界值;实验室异常包括INR 6.43、血清肌酐2.21 mg/dL。
- 给药30分钟后复查PT/INR分别为16.1 s和1.55。
处置流程与药物剂量
- 第一步:对失代偿性休克患者行气管插管、积极晶体液复苏、输注血制品并启动血管升压药。
- 第二步:因无法区分华法林与达比加群所致凝血病且缺乏医疗信息,为预防血栓前状态,未使用凝血酶原复合物(PCC)。
- 第三步:仅使用依达赛珠单抗进行逆转(原文未提及具体剂量、给药途径及频次)。
- 第四步:给药30分钟后复查PT/INR,结果为16.1 s和1.55。
红旗征与不能漏的情况
- 用药史不明且INR极度升高(6.43)的出血患者,需警惕达比加群所致凝血病可能模拟华法林性凝血病,尤其在急性肾衰竭(肌酐2.21 mg/dL)时。
- 患者出现失代偿性休克需气管插管、晶体液复苏、血制品及血管升压药,属需立即处理的危重情况。
研究设计与关键结果
- 研究类型:病例报告;样本量:1例;中心数:原文未提及。
- 人群:85岁女性,用药史不明,上消化道出血导致呼吸困难、严重贫血及失代偿性休克。
- 干预:因无法区分华法林与达比加群所致凝血病,未用PCC,仅用依达赛珠单抗逆转。
- 主要终点结果:给药30分钟后PT/INR从6.43降至1.55,PT降至16.1 s;后证实患者仅服用达比加群。
- 关键次要终点及不良事件:原文未提及。
证据类型、等级与局限
- 证据类型:病例报告(单例)。
- 证据等级或推荐强度:原文未提及。
- 局限:单中心、单例、回顾性描述,无法确立因果关系或推广至其他人群;原文未提及具体剂量及给药方案。
对床旁实践的改变
- 对于用药史不明、INR极度升高且伴急性肾衰竭的出血患者,达比加群所致凝血病应纳入鉴别诊断,避免误判为华法林性凝血病。
- 在无法区分华法林与达比加群所致凝血病时,本病例做法为不用PCC、仅用依达赛珠单抗逆转,但此为单例经验,需结合临床判断。
- 依达赛珠单抗可在30分钟内快速纠正达比加群相关的PT/INR升高,但原文未提供剂量及给药方案,不能据此形成通用推荐。
- 适用与不适用人群:原文仅报告一例85岁女性,无明确适用/不适用人群标准;常见陷阱为将达比加群所致INR升高误认为华法林性凝血病而错误使用PCC。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Dabigatran is a direct oral anticoagulant thrombin inhibitor approved for stroke prophylaxis in patients with non-valvular atrial fibrillation and prophylaxis or treatment of venous thromboembolism. Since approval, there has been increasing concern regarding bleeding risk, predominantly in the elderly population and those with renal disease. We present a case of an 85-year-old female with an unknown medication history, shortness of breath and severe anemia due to an upper gastrointestinal bleed. Laboratory abnormalities were significant for INR 6.43 and serum creatinine 2.21 mg/dL. While in the emergency department the patient decompensated requiring intubation, aggressive crystalloid resuscitation, blood products and initiation of vasopressors. The inability to distinguish between warfarin- and dabigatran-induced coagulopathies paired with the lack of medical information complicated selection of the appropriate anticoagulation reversal agent. In an attempt to prevent a prothrombotic state, prothrombin complex concentrates (PCC) were held and reversal was accomplished with idarucizumab alone, although warfarin-induced coagulopathy remained a possibility. 30 min after administration, repeat PT/INR was 16.1 s and 1.55, respectively. It was later confirmed that the patient was on sole dabigatran therapy. This case highlights the potential for dabigatran to cause extreme elevation in PT/INR in patients with acute renal failure, which may mimic warfarin-induced coagulopathy. Further, it demonstrates significant, rapid correction of abnormal coagulation assays following administration of idarucizumab in a patient with severe INR elevation and suspected dabigatran use.
参考来源
- Kutner S, Scaturo N, Williams B, et al. Idarucizumab (PRAXBIND®) as a sole reversal agent in an unstable hemorrhagic shock patient on an unknown anticoagulant with elevated protime/international normalized ratio (PT/INR). Am J Emerg Med. 2021. PMID: 33612323. doi:10.1016/j.ajem.2021.01.086
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。